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Abstract: Purpose. The purpose of this study was to deter-
mine whether serum vascular endothelial growth factor (s-VEGF)
levels at the time of diagnosis correlate with any known tumor
variables and overall survival in patients with advanced laryngeal
squamous cell carcinoma. Comparisons with a cohort of normal
healthy controls were also performed to determine the potential
usefulness of s-VEGF as a screening tool.
Experimental Design. Serum from patients enrolled in the VA
Laryngeal Cooperative Study #258 (n = 183), as well as normal
healthy controls (n = 40) was used in this analysis. Quantitative
enzyme-linked immunosorbent assays (ELISA) for VEGF were
performed in duplicate on each serum sample. Demographic and
survival data were available for each patient enrolled in the study.
Univariate analyses, multivariate Cox regression analyses, and
Kaplan-Meier survival analysis were used.
Results. The mean serum concentration of s-VEGF for the
healthy control group was 47.83 ± 0.13 pg/mL. For all patients
enrolled in the VA Cooperative Study, regardless of treatment
group, the mean s-VEGF level was 317.22 ± 25.46 pg/mL. The
patients randomly assigned to the surgical arm (n = 97) had a
mean value of 315.44 ± 30.44 pg/mL. Those randomly assigned
to the induction chemotherapy arm (n = 86) had a mean s-VEGF
level of 319.22 ± 42.11 pg/mL. Serum VEGF levels were signifi-
cantly elevated in patients with laryngeal carcinoma compared
with healthy controls (p < .001). The serum VEGF levels in each
arm of the trial were also elevated versus the healthy controls (p
< .001, surgery arm plus radiotherapy; p < .001, chemotherapy
plus radiotherapy). In a univariate analysis, elevated s-VEGF cor-
related with poor Karnofsky performance status for all patients
with advanced laryngeal carcinoma (p < .008). High s-VEGF lev-
els also correlated with a poor performance score in patients on
the chemotherapy arm of the VA Laryngeal Trial (p < .004). El-
evated s-VEGF levels in the surgical plus radiotherapy arm cor-
related with node-positive disease (p = .047) and supraglottic
location of the tumor (p = .022). In a multivariate analysis using all
known tumor variables and s-VEGF levels, elevated s-VEGF lev-
els and infiltrating growth pattern correlated with decreased sur-
vival for all evaluated patients with advanced laryngeal carci-
noma (p = .065, and p = .018, respectively).
Conclusions. Serum VEGF levels are significantly elevated in
patients with advanced laryngeal carcinoma versus healthy con-
trols. Elevated pretreatment s-VEGF levels tended to indicate a
more aggressive disease state and a poorer overall survival in
advanced laryngeal carcinoma. © 2002 Wiley Periodicals, Inc.
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Angiogenesis is the process of new blood vessel
formation. It is encountered in essential physi-
ologic processes (eg, endometrial proliferation,
embryogenesis, wound healing), as well as in mul-
tiple pathologic conditions (eg, rheumatoid arthri-
tis, diabetic retinopathy, neoplastic diseases).1
Folkman and coworkers2 pioneered the concept
that primary or metastatic tumors must become
vascularized to exceed 2 mm. On the basis of ani-
mal data, Folkman et al3 found that tumor angio-
genesis must precede tumor growth and that tu-
mor progression can only occur when neoplasms
switch from a prevascular to an angiogenic phase.
Vascular endothelial growth factor (VEGF) is one
of the most potent angiogenic factors discovered
to date. Also known as vascular permeability fac-
tor (VPF), VEGF stimulates angiogenesis by in-
creasing vascular permeability and by acting as
an endothelial cell mitogen.4 Several studies have
reported that elevated levels of serum VEGF (s-
VEGF) portend a poor prognosis in a variety of
solid tumors.5–10 Furthermore, Qian et al11 have
linked s-VEGF levels to metastatic disease in na-
sopharyngeal carcinoma. However, data related
to other head and neck sites are lacking.
The purpose of this study was to determine
whether s-VEGF levels, at the time of diagnosis,
correlate with response to treatment and overall
survival in patients with locally advanced laryn-
geal cancer. Comparisons with a cohort of normal
healthy controls were also performed to deter-
mine the potential usefulness of s-VEGF as a
screening tool.
MATERIALS AND METHODS
Patient Population. A total of 332 patients with
stage III (188 patients) or stage IV (144 patients)
squamous cell carcinoma of the larynx were en-
rolled in the prospective clinical trial entitled
“The Department of Veteran’s Affairs Coopera-
tive Studies Laryngeal Cancer Study #268.”12
This cooperative study was reviewed and ap-
proved by the institutional review boards of all
participating institutions. Informed consent was
obtained from each patient at the time of accrual.
Half of the patients enrolled in the study (166
patients) were randomly assigned to receive con-
ventional surgery and postoperative radiation
therapy (50–65 cGy). The other half (166 patients)
received three cycles of induction chemotherapy
(cis-platinum, 100 mg/m2 on day 1 and 5-fluoro-
uracil, 1000 mg/m2 per day, on days 1 through 5)
and radiation therapy (66–76 cGy). Surgical sal-
vage was performed on those patients who failed
to respond after two cycles of chemotherapy or on
those with persistent or recurrent disease at the
completion of treatment. This treatment regimen
and study results have previously been described
in detail.12 The sera used in this study were col-
lected from each patient before treatment. It was
centrifuged at 3000 × g for 15 min and frozen at
−80°F until analysis. Ninety-seven samples from
individual patients randomly assigned to the sur-
gical arm of treatment and 86 samples from pa-
tients randomly assigned to treatment with che-
motherapy were available for analysis. Forty
serum samples from normal healthy volunteers
were used as controls.
Serum VEGF Immunoassay. A quantitative, en-
zyme-linked immunosorbent assay (ELISA) was
performed in duplicate on each sample to mea-
sure the concentration of soluble serum VEGF. A
commercially available ELISA kit was used
(Quantikine Human VEGF Immunoassay, R&D
Systems, Minneapolis MN). Serum samples from
all patients were incubated for 2 hours at room
temperature in duplicate (100 L) on microtiter
plates coated with a monoclonal antibody specific
for VEGF. Next, any unbound substances were
washed away, and an enzyme-linked polyclonal
antibody specific for VEGF was introduced. This
was allowed to incubate for 2 hours at room tem-
perature, and the plates were washed to remove
unbound antibody. A substrate solution was
added, and color development was stopped after
25 minutes at room temperature. A microplate
reader was then used to determine colorimetric
densities at 570 nm and 450 nm for each sample.
The optical density for each sample was deter-
mined by subtracting the readings at 570 nm
from the reading at 450 nm. Results were calcu-
lated from a standard curve generated by a form
parametric logistic curve fit and expressed in pg/
mL of serum. The test sensitivity as determined
by the manufacturer is <9.0 pg/mL.
Statistical Analysis. All values are presented as
mean ± standard error. Student’s t test was used
to detect differences between groups in continu-
ous measures. Serum VEGF levels per specimen
were compared between normal, healthy volun-
teers and laryngeal cancer patients using Stu-
dent’s t test. Student’s t test was also used to
determine whether there was a significant differ-
ence in s-VEGF levels among different categorical
variables including clinical stages, T stages, N
stages, Karnofsky performance scale scores, ages,
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growth patterns, treatment groups, and tumor
sites. Survival analyses were conducted using the
Kaplan-Meier technique; differences between dis-
tributions were compared using the log-rank test.
Survival was calculated for each patient from the
VA Larynx study randomization date to the date
of death; patients remaining alive were censored
at the date last known to be alive. A multivariate
Cox regression model was used, and the number
of covariates included s-VEGF (pg/mL), growth
pattern (1 or 2 vs 3 or 4 as described by Jakobs-
son13), treatment group (chemo/XRT vs surgery/
RT), stage (1–3 vs 4), site (glottic vs supraglottic),
age, and T stage (1–3 vs 4). For all analyses, a
two-sided alpha level of .05 was considered sta-
tistically significant.
RESULTS
Patient Descriptive Data. There were a total of
183 patients with serum samples available for
analysis from the 332 patients enrolled in the VA
Laryngeal Cooperative Study. Ninety-seven were
from the surgery arm and eighty-six were from
the chemotherapy arm of the trial. For inclusive
data on all the subjects refer to Table 1.
Most patients (112 of 183) had stage III tu-
mors. The most common T stage was T3 (125 of
183), and the most common nodal status was N0
(105 of 183). Most tumors were supraglottic (116
of 183). Accurately reflecting the VA population,
most patients were men (179 of 183) and white
(142 of 183).
Serum VEGF Levels in Normal Controls vs Laryngeal
Cancer Patients. The mean serum concentration
of s-VEGF for the healthy control group was 47.83
± 0.13 pg/mL. For all patients in the VA Coopera-
tive Study, regardless of treatment group, the
mean s-VEGF level was 317.22 ± 25.46 pg/mL.
The patients randomly assigned to the surgery
arm (97 patients) had a mean value of 315.44 ±
30.44 pg/mL. Those randomly assigned to the in-
duction chemotherapy arm (86 patients) had a
mean s-VEGF level of 319.22 ± 42.11. Serum
VEGF levels were significantly elevated in pa-
tients with laryngeal carcinoma compared with
healthy controls (p < .001). Also, when analyzed
by treatment arm, each group had significantly
elevated s-VEGF compared with the healthy con-
trols (surgery plus RT, p < .001; induction chemo-
therapy plus RT, p < .001). When comparing the
s-VEGF levels in the two arms of the VA Laryn-
geal Study, there was no significant difference in
s-VEGF levels (p  .941), as expected.
Correlation of S-VEGF Levels with Known Tumor Fac-
tors. Serum VEGF levels were compared in re-
lation to a variety of known tumor prognostic
variables. These variables included stage, T
stage, N stage, site, race, growth pattern, and
Karnofsky performance scale. Table 2 summa-
rizes the results. When s-VEGF levels from pa-
tients in both arms of the trial are included in the
analysis, the only factor that s-VEGF was signifi-
cantly correlated with was Karnofsky Perfor-
mance Scale (p  .008). High s-VEGF levels cor-
related with performance scores less than 80,
whereas levels below the mean correlated with
performance scores greater than 80. In patients
randomly assigned to the induction chemo-
therapy arm, the s-VEGF levels were also signifi-
cantly different between high and low perfor-
mance status groups (p  .004), but no other
variables reached statistical significance. On the
Table 1. Demographic data of study patients.
Surgery arm Chemo arm Total
Stage
III 59 53 112
IV 38 33 71
T stage
1 3 2 5
2 7 4 11
3 64 61 125
4 23 19 42
N stage
0 58 47 105
1 15 17 32
2 14 10 24
3 10 12 22
Tumor site
Glottic 35 31 66
Supraglottic 61 55 116
Subglottic 1 0 1
Performance status
60 4 5 9
70 16 16 32
80 30 19 49
90 44 36 80
100 3 10 13
Sex
M 95 84 179
F 2 2 4
Race
White 83 59 142
Black 13 25 38
Other 1 2 3
Tumor growth pattern
1 0 3 3
2 55 45 100
3 14 24 38
4 4 3 7
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other hand, in patients randomly assigned to the
surgical arm, s-VEGF levels were lower in N0 vs
N+ patients (p  .047) and between those pa-
tients with glottic tumors vs those with supraglot-
tic tumors (p  .022). No other variables, includ-
ing performance scores, reached significance in
the surgical arm patients.
Correlation of Serum VEGF Levels with Overall Sur-
vival in Patients with Advanced Laryngeal Can-
cer. Serum concentration of VEGF lacks a
clearly defined cutoff level. It was determined a
priori that differences in patient survival would
be based on a comparison of subjects having an
s-VEGF level of greater than the sample mean
plus one standard deviation versus all other sub-
jects. Using this cutoff, elevated s-VEGF was sig-
nificantly associated with reduced survival in the
surgical arm of the VA Larynx Study (p  .018)
but not in the chemotherapy arm (p  .90), as
shown in the Kaplan-Meier survival curve analy-
sis (see Figure 1). In a Cox regression model using
VEGF as a continuous variable, once again el-
evated s-VEGF was associated with reduced sur-
vival in the surgical arm (p  .0311) but not in
the chemotherapy arm (p  .919). In a multivari-
ate Cox regression model for overall survival, us-
ing s-VEGF levels from both arms of the trial and
all the known tumor variables as covariates, s-
VEGF nearly obtained statistical significance (p
 .065, see Table 3). Impressively, it did have the
highest relative risk, imparting a 47% increased
risk of death. The only variable significantly as-
sociated with reduced survival was aggressive
growth pattern, and it imparted a 44% increased
risk of death. When performing multivariate
analysis in each arm of the trial individually us-
ing the same covariates, no variables were found
to be correlated with poor overall survival in the
chemotherapy arm (Tables 4 and 5). In the sur-
gery arm, aggressive growth pattern correlated
with poor survival (p  .011); however, no other
variables reached significance, including s-VEGF
(Table 4).
DISCUSSION
VEGF is one of the most potent factors respon-
sible for inducing tumor angiogenesis.4 It is a di-
meric glycoprotein with at least six spliced vari-
ants containing 115, 121, 145, 165, and 206 amino
acid residues.14–16 Each variant expresses identi-
cal biologic activity by binding to specific class III
tyrosine receptor kinases (flt-1 and KDR).14–16
VEGF is expressed in both normal and neoplastic
cells, where it acts as an endothelial cell mitogen.
VEGF mRNA has been found to be overexpressed
in tumor cells, and secreted VEGF has been local-
ized to the supplying vascular endothelium of tu-
Table 2. Univariate analyses comparing serum VEGF levels with known tumor variables.
All patients Surgery arm Induction chemo arm
Serum VEGF levels p Value Serum VEFG levels p Value Serum VEGF levels p Value
Karnofsky PS
80 386.18 (n = 90) * 331.43 (n = 50) 454.62 (n = 40) *
>80 250.48 (n = 95) .008 329.44 (n = 47) .591 201.47 (n = 46) .004
Growth pattern
1 or 2 314.80 (n = 103) 293.90 (n = 55) 338.80 (n = 48)
3 or 4 316.64 (n = 45) .977 333.80 (n = 18) .605 305.20 (n = 27) .736
Stage
3 297.71 (n = 112) 287.11 (n = 59) 296.83 (n = 53)
4 357.45 (n = 71) .209 359.43 (n = 38) .248 355.17 (n = 33) .504
Tumor stage
T1–3 307.09 (n = 141) 325.59 (n = 74) 286.65 (n = 67)
T4 351.22 (n = 42) .468 382.79 (n = 23) .552 434.07 (n = 19) .147
Node stage
N0 306.23 (n = 105) 261.61 (n = 58) * 361.30 (n = 47)
N1–3 332.00 (n = 78) .618 395.51 (n = 39) .047 268.49 (n = 39) .267
Site
Supra/subglottic 340.12 (n = 117) 361.81 (n = 62) * 315.68 (n = 55)
Glottic 276.61 (n = 66) .232 233.30 (n = 35) .022 325.50 (n = 31) .812
Race
Caucasian 296.75 (n = 142) 300.34 (n = 83) 271.70 (n = 59)
All others 388.10 (n = 41) .258 404.98 (n = 14) .225 379.35 (n = 27) .337
*Statistical significance.
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mor cells.17 Deficiencies in critical nutrients, me-
tabolites, and oxygen are also shown to facilitate
VEGF mRNA expression in tumor cells.18
Serum concentration of VEGF has been inves-
tigated in numerous human malignancies, includ-
ing melanoma, non-Hodgkin’s lymphoma, renal
cell carcinoma, brain, colorectal, small cell lung,
and vulvar carcinoma.6,7,8,14,19 In these studies,
elevated serum VEGF correlated with poor prog-
nosis. To date, there exists no prospective study
evaluating the usefulness of s-VEGF as a prog-
nostic factor in human squamous cell carcinoma
of the head and neck. Qian et al11 have evaluated
serum VEGF levels in nasopharyngeal carci-
noma. In their study, they analyzed s-VEGF lev-
els in normal controls, patients with nonmeta-
static nasopharyngeal carcinoma, and patients
with metastatic nasopharyngeal carcinoma. What
they found was that s-VEGF levels >900 pg/mL
indicated metastasis with a high specificity
(95.4%) and a low sensitivity (31.8%). The weak-
ness of this study, as stated by the authors, was
that it was not a prospective study and that cor-
Table 3. Cox proportional hazards multivariable regression of
parameters potentially influencing overall survival in advanced
laryngeal cancer patients.
Variable Risk ratio p Value





T stage 1.059 .733
Growth pattern 1.441 .018
Table 4. Cox proportional hazards multivariable regression of
parameters potentially influencing overall survival in advanced
laryngeal cancer patients treated by surgery.
Variable Risk ratio p Value




T stage 0.991 .968
Growth pattern 1.834 .012
FIGURE 1. Kaplan-Meier curve survival analyses for the two arms of the VA laryngeal cooperative study #268. Based on VEGF level
there was no significant difference in survival distributions in the induction chemotherapy and radiation therapy arm. There was, however,
a highly statistically significant difference between patients with a low level of angiogenesis versus those with a high level of angiogenesis
in the surgical arm. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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relation with outcome should be made on pre-
treatment VEGF levels. This is exactly what our
study has investigated. The VA Laryngeal Coop-
erative Study #268 provides a unique opportunity
to investigate the usefulness of serum VEGF lev-
els, because pretreatment serum is available on
the study patients and detailed data exist on the
patients’ tumors at the time of presentation. Fur-
thermore, very accurate longitudinal follow-up
data exist on all the patients included in this
study. Altogether, this may allow important con-
clusions to be drawn concerning pretreatment
VEGF levels in advanced laryngeal carcinoma.
The most significant finding in our study is
that pretreatment s-VEGF was an independent
predictor of overall survival in advanced laryn-
geal cancer patients. In our multivariate analysis,
in which all known risk factors for tumor recur-
rence were included as covariates, elevated s-
VEGF levels were associated with decreased over-
all survival, and serum values greater than the
mean imparted a 47% increased risk of death (p
 .065, RR  1.47, CI  0.98–2.23). Although
with a two-sided p value it just failed to reach
statistical significance, the only factor with a
stronger correlation than s-VEGF level was ag-
gressive histologic growth pattern. Despite reach-
ing statistical significance (p  .0179), it im-
parted only a 44% increased risk of death (RR 
1.441, 95% CI  1.06–1.95). Further compelling
data in illustrating the importance of s-VEGF
were that it was more strongly correlated with
ultimate survival than stage, site, T stage, and N
status, which have historically been considered
major determinants of overall survival. Similar
findings linking increased s-VEGF with poor
overall survival in multivariate analyses have
been documented in other malignant neoplasms
such as breast, lung, ovarian, and brain tu-
mors.20,21 In head and neck cancer, Eisma et al22
showed that tissue levels of VEGF and IL-8 cor-
related with more aggressive disease, higher
TNM stage, more recurrences, and shorter dis-
ease-free survival. Similary, Chen et al23 illus-
trated that elevated s-VEGF and IL-8 correlated
with large primary tumor volume. Although these
reports point to findings similar to ours, a notable
difference is that s-VEGF in our study did not
correlate with the stage of disease. This is likely
due to the preponderance of T3 tumors in our
study, which can vary markedly in tumor volume
according to the size of the primary tumor.
When the two arms of the VA Larynx trial
were looked at individually using Kaplan-Meier
survival curve analysis, elevated s-VEGF was sig-
nificantly associated with poorer overall survival
in the surgical arm (p  .0018) but not in the
chemotherapy arm of the trial. Likewise, using
Cox regression analysis with s-VEGF as a con-
tinuous variable, elevated s-VEGF was signifi-
cantly associated with poor survival in the surgi-
cal arm (p  .0311) but not in the induction
chemotherapy group (p  .1091). Knowing that
s-VEGF levels correlated with survival in a mul-
tivariate analysis of all patients, the question
arose as to why the difference existed between the
two groups. One possibility is that s-VEGF, as a
reflection of tumor angiogenesis, is negated as a
predictive factor by the use of the chemotherapeu-
tic agents themselves. In a theory first proposed
by Denekamp in 1982,24,25 rapidly dividing endo-
thelial cells in newly formed tumor blood vessels
may render such vessels sensitive to the cytotoxic
effects of chemotherapy, much like rapidly divid-
ing cells in hair follicles, bone marrow, and ali-
mentary tract mucosal cells.26 This “collateral
damage” to the tumor vasculature could contrib-
ute to the antitumor efficacy of chemotherapy and
make s-VEGF less likely to be a predictive factor
for overall survival in the induction chemo-
therapy group. To support this hypothesis, we
performed multivariate analyses in each arm of
the VA Larynx trial using the same variables in-
cluding s-VEGF. We theorized if s-VEGF was not
an independent predictor of survival in the che-
motherapy arm but was significant in the surgical
arm, this would lend some credence to this argu-
ment. The multivariate analyses, however, failed
to reveal a correlation in either arm with s-VEGF
levels. In all likelihood, the most plausible expla-
nation as to why s-VEGF correlated with survival
for the entire group of patients but not in each
individual arm is strictly related to statistical
power. There was a good deal of variability in s-
VEGF levels throughout the patient population;
Table 5. Cox proportional hazards multivariable regression of
parameters potentially influencing overall survival in advanced
laryngeal cancer patients treated with chemotherapy and
radiation therapy.
Variable Risk ratio p Value




T stage 1.082 .755
Growth pattern 1.278 .228
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therefore, a larger number of patients was neces-
sary to show correlation with overall survival.
This concept that chemotherapy has an antian-
giogenic effect remains appealing, however, and
merits consideration in future analyses with
larger groups of patients.
Another important finding in this study is that
s-VEGF levels were markedly elevated in pa-
tients with advanced laryngeal carcinoma vs nor-
mal healthy controls (319.22 vs 47.83, p < .001).
Furthermore, the serum VEGF levels between
the two arms of the VA Larynx trial (surgery/RT
vs induction chemotherapy/RT) were not different
from each other as expected (0.941) because of the
similar tumor staging in both groups. This raises
the possibility that s-VEGF may be a candidate
biomarker of tumor presence in head and neck
patients. In renal cell carcinoma, Baccala et al27
have shown a decrease in serum VEGF with tu-
mor response to therapy and an increase with re-
currence. Studies in nasopharyngeal carcinoma
have also shown that s-VEGF may be a biomarker
for metastasis.11 To further investigate this pos-
sibility, however, a prospective trial would need
to be performed, with serial s-VEGF levels being
drawn and correlated with clinical tumor param-
eters.
Finally, it is important to note that elevated
s-VEGF correlated with a poor performance sta-
tus (p  .008) in all patients with advanced la-
ryngeal cancer. In patients randomly assigned to
the surgical arm of the trial, s-VEGF levels were
also elevated in those initially seen with ad-
vanced nodal status (p  .047) and supraglottic
location of tumor (p  .022). The explanation for
all these observations may be that high s-VEGF
levels are present in the most aggressive tumors
and thus result in greater patient disability.
Several aspects of this study may be perceived
as deficiencies and must be expanded on. One of
these lies in the fact that platelet counts were not
available for the subjects in our study. It has been
shown that s-VEGF levels correlate with platelet
counts in various human malignancies.28 This is a
factor in our study that we were unable to control
for, because only serum was available for analy-
sis. Other factors such as menstruation and medi-
cations that could affect s-VEGF levels were also
not taken into account because of lack of data.
There were, however, very few women in this
study, making menstruation a factor of negligible
significance. The use of banked frozen serum for
analysis may also be perceived as a deficiency in
our study. According to Jacobsen et al,21 however,
storage time from 2 to 16 years showed no trend
or shift on analyzed s-VEGF levels, illustrating
the stability of this compound and validating our
research design. Finally, it is unfortunate that
serial serum samples were not available at vari-
ous points during the treatment cycles. This
would have provided critical information in terms
of s-VEGF level changes in response to treatment
and its use as a biomarker for laryngeal cancer.
We are currently performing such studies in other
laryngeal preservation protocols.
CONCLUSIONS
1. Pretreatment s-VEGF levels in advanced la-
ryngeal carcinoma were an independent pre-
dictor of overall survival in the VA Laryngeal
Cooperative Study Group Trial #268.
2. Healthy volunteers had a significantly lower
s-VEGF level than advanced laryngeal cancer
patients, indicating that s-VEGF may be a
valuable serum marker for detecting laryngeal
squamous cell carcinoma.
3. Laryngeal cancer patients with lower perfor-
mance statuses tended to have significantly el-
evated s-VEGF levels.
4. Elevated serum VEGF levels in the surgical
arm of the VA Laryngeal Study correlated
with advanced nodal disease, supraglottic lo-
cation of tumor, and decreased overall sur-
vival.
5. Overall, there were many indications in this
report of elevated s-VEGF levels correlating
with aggressive disease and poor prognosis.
Further investigations are warranted to ex-
plain the importance of this systemically de-
tected marker of angiogenesis.
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